Overview
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
Eligibility
Inclusion Criteria:
- Signs of Demodex blepharitis in at least one eye
- Best Spectacle Corrected Visual Acuity (BSCVA) of 20/80 Snellen or better in each eye
Exclusion Criteria:
- Presence of eczema or dermatitis in the ocular region of either eye
- Use of lid hygiene products within 14 days of Screening
- Active ocular infection or inflammation, other than blepharitis, in either eye at Screening
- Women who are pregnant, planning a pregnancy, or nursing
- Have used an investigational drug or device within 30 days prior to Screening or concurrently enrolled in another investigational drug or device trial


